Burzynski Research Institute (BZYR) Depreciation & Amortization (CF) (2010 - 2017)
Burzynski Research Institute (BZYR) posted Depreciation & Amortization (CF) of $171.0 for Q1 2017, little changed sequentially from $171.0 in Q4 2016, and little changed YoY from $171.0 in Q1 2016.
Burzynski Research Institute (BZYR) Depreciation & Amortization (CF) (2010 - 2017) Analysis & Trends
Burzynski Research Institute has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $171.0 in Q1 2017.
- Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $171.0 in Q1 2017, while the trailing twelve-month figure through Nov 2017 was $171.0 (down 75.0% YoY) and the FY2017 annual result came in at $684.0, changed 0.0% from the prior year.
- Depreciation & Amortization (CF) held at $171.0 in Q1 2017 per BZYR's latest filing, from $171.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $171.0 in Q2 2013 and troughed at $170.0 in Q1 2013.
- A 5-year average of $170.94 and a median of $171.0 in 2013 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2013 and 2014: Depreciation & Amortization (CF) changed 0.0% in 2013, then increased 0.59% in 2014.
- Over 5 years, Depreciation & Amortization (CF) stood at $171.0 in 2013, then changed by 0.0% to $171.0 in 2014, then changed by 0.0% to $171.0 in 2015, then changed by 0.0% to $171.0 in 2016, then changed by 0.0% to $171.0 in 2017.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $171.0, $171.0, and $171.0 for Q1 2017, Q4 2016, and Q3 2016 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2017 | 171.00 |
| Feb 28, 2017 | 171.00 |
| Nov 30, 2016 | 171.00 |
| Nov 30, 2016 | 171.00 |
| Aug 31, 2016 | 171.00 |
| Aug 31, 2016 | 171.00 |
| May 31, 2016 | 171.00 |
| May 31, 2016 | 171.00 |
| Feb 29, 2016 | 171.00 |
| Feb 29, 2016 | 171.00 |
| Nov 30, 2015 | 171.00 |
| Nov 30, 2015 | 171.00 |
| Aug 31, 2015 | 171.00 |
| Aug 31, 2015 | 171.00 |
| May 31, 2015 | 171.00 |
| May 31, 2015 | 171.00 |
| Feb 28, 2015 | 171.00 |
| Feb 28, 2015 | 171.00 |
| Nov 30, 2014 | 171.00 |
| Nov 30, 2014 | 171.00 |